INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 460m ago
HOUSE PTR59m ago
SEC 13F59m ago
ROBINHOOD CHAIN59m ago
Public company

Structure Therapeutics Inc.

GPCRCIK 0001888886

EDGAR filingsOpen in network
Price$20.35
1 year-36.8%
Disclosed transactions40
Buys / sells0 / 8
Max Insider Score23
Connections with evidence9

GPCR · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
2
CB
Coll Crespo BlasCHIEF MEDICAL OFFICER
GPCRStructure Therapeutics Inc.
Tax withholding · 10b5-1 plan
F$124K
10.6K sh
Sep 18, 2026Sep 22, 2026

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Holds over 5% ofevidence
    FMR LLC15% of class · Schedule 13G · Nov 4, 2026
  • ← Insider ofevidence
    Berrios John JosephChief Commercial Officer · Aug 7, 2026
  • ← Insider ofevidence
    Waldstreicher JoanneDirector · Jun 18, 2026
  • ← Insider ofevidence
traded Sep 18, 2026
+4d
SEC FORM 4

Evidence

20
CB
Coll Crespo BlasCHIEF MEDICAL OFFICER
GPCRStructure Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$145K
4,008 sh
Sep 21, 2026Sep 22, 2026
traded Sep 21, 2026
+1dSEC FORM 4

Evidence

11
CB
Coll Crespo BlasCHIEF MEDICAL OFFICER
GPCRStructure Therapeutics Inc.
Derivative conversion · 10b5-1 plan
C—
4,008 sh
Sep 21, 2026Sep 22, 2026
traded Sep 21, 2026
+1dSEC FORM 4

Evidence

0
CB
Coll Crespo BlasCHIEF MEDICAL OFFICER
GPCRStructure Therapeutics Inc.
Derivative conversion · 10b5-1 plan
C—
12.0K sh
Sep 21, 2026Sep 22, 2026
traded Sep 21, 2026
+1dSEC FORM 4

Evidence

0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Derivative conversion · 10b5-1 plan
C—
17.8K sh
Sep 1, 2026Sep 2, 2026
traded Sep 1, 2026
+1dSEC FORM 4

Evidence

0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Option exercise · 10b5-1 plan
M$6,058
17.8K sh
Sep 1, 2026Sep 2, 2026
traded Sep 1, 2026
+1dSEC FORM 4

Evidence

12
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$60K
1,300 sh
Sep 1, 2026Sep 2, 2026
traded Sep 1, 2026
+1dSEC FORM 4

Evidence

0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
17.8K sh
Sep 1, 2026Sep 2, 2026
traded Sep 1, 2026
+1dSEC FORM 4

Evidence

16
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$214K
4,539 sh
Sep 1, 2026Sep 2, 2026
traded Sep 1, 2026
+1dSEC FORM 4

Evidence

13
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$4,783
100 sh
Sep 1, 2026Sep 2, 2026
traded Sep 1, 2026
+1dSEC FORM 4

Evidence

0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Derivative conversion · 10b5-1 plan
C—
5,939 sh
Sep 1, 2026Sep 2, 2026
traded Sep 1, 2026
+1dSEC FORM 4

Evidence

0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Option exercise · 10b5-1 plan
M$4,018
11.8K sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

16
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$160K
3,020 sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

13
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$28K
519 sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
11.8K sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Derivative conversion · 10b5-1 plan
C—
3,939 sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

13
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$22K
400 sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Derivative conversion · 10b5-1 plan
C—
11.8K sh
Aug 18, 2026Aug 19, 2026
traded Aug 18, 2026
+1dSEC FORM 4

Evidence

9
BJ
Berrios John JosephChief Commercial Officer
GPCRStructure Therapeutics Inc.
Grant or award
A—
174.6K sh
Aug 6, 2026Aug 7, 2026
traded Aug 6, 2026
+1dSEC FORM 4

Evidence

9
BJ
Berrios John JosephChief Commercial Officer
GPCRStructure Therapeutics Inc.
Grant or award
A—
140.8K sh
Aug 6, 2026Aug 7, 2026
traded Aug 6, 2026
+1dSEC FORM 4

Evidence

0
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Derivative conversion · 10b5-1 plan
C—
7,878 sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

23
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Open-market sale · 10b5-1 plan
SELL$387K
7,878 sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

3
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Option exercise · 10b5-1 plan
M$8,036
23.6K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

3
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Derivative conversion · 10b5-1 plan
C—
23.6K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

3
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Option exercise · 10b5-1 plan
M—
23.6K sh
Jun 25, 2026Jun 29, 2026
traded Jun 25, 2026
+4dSEC FORM 4

Evidence

9
WJ
Waldstreicher JoanneDirector
GPCRStructure Therapeutics Inc.
Grant or award
A—
39.5K sh
Jun 17, 2026Jun 18, 2026
traded Jun 17, 2026
+1dSEC FORM 4

Evidence

19
LM
Lang MatthewCOO & GC
GPCRStructure Therapeutics Inc.
Grant or award
A—
223.8K sh
Apr 15, 2026Apr 23, 2026
traded Apr 15, 2026
+8dSEC FORM 4

Evidence

19
LM
Lang MatthewCOO & GC
GPCRStructure Therapeutics Inc.
Grant or award
A—
184.6K sh
Apr 15, 2026Apr 23, 2026
traded Apr 15, 2026
+8dSEC FORM 4

Evidence

17
CB
Coll Crespo BlasCHIEF MEDICAL OFFICER
GPCRStructure Therapeutics Inc.
Grant or award
A—
75.9K sh
Mar 19, 2026Mar 23, 2026
traded Mar 19, 2026
+4dSEC FORM 4

Evidence

17
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Grant or award
A—
43.4K sh
Mar 19, 2026Mar 23, 2026
traded Mar 19, 2026
+4dSEC FORM 4

Evidence

9
MY
Ma YingliCHIEF TECHNOLOGY OFFICER
GPCRStructure Therapeutics Inc.
Grant or award
A—
40.3K sh
Mar 19, 2026Mar 23, 2026
traded Mar 19, 2026
+4dSEC FORM 4

Evidence

9
CB
Coll Crespo BlasCHIEF MEDICAL OFFICER
GPCRStructure Therapeutics Inc.
Grant or award
A—
94.0K sh
Mar 19, 2026Mar 23, 2026
traded Mar 19, 2026
+4dSEC FORM 4

Evidence

9
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Grant or award
A—
53.7K sh
Mar 19, 2026Mar 23, 2026
traded Mar 19, 2026
+4dSEC FORM 4

Evidence

13
YJ
Yoon JunCHIEF FINANCIAL OFFICER
GPCRStructure Therapeutics Inc.
Grant or award
A—
104.1K sh
Mar 19, 2026Mar 23, 2026
traded Mar 19, 2026
+4dSEC FORM 4

Evidence

17
MY
Ma YingliCHIEF TECHNOLOGY OFFICER
GPCRStructure Therapeutics Inc.
Grant or award
A—
32.5K sh
Mar 19, 2026Mar 23, 2026
traded Mar 19, 2026
+4dSEC FORM 4

Evidence

9
YJ
Yoon JunCHIEF FINANCIAL OFFICER
GPCRStructure Therapeutics Inc.
Grant or award
A—
128.9K sh
Mar 19, 2026Mar 23, 2026
traded Mar 19, 2026
+4dSEC FORM 4

Evidence

19
LX
Lin XichenCHIEF SCIENTIFIC OFFICER
GPCRStructure Therapeutics Inc.
Tax withholding
F$393K
18.7K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

16
CB
Coll Crespo BlasCHIEF MEDICAL OFFICER
GPCRStructure Therapeutics Inc.
Tax withholding
F$248K
11.8K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

15
YJ
Yoon JunCHIEF FINANCIAL OFFICER
GPCRStructure Therapeutics Inc.
Tax withholding
F$468K
22.3K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

16
MY
Ma YingliCHIEF TECHNOLOGY OFFICER
GPCRStructure Therapeutics Inc.
Tax withholding
F$237K
11.3K sh
Mar 3, 2026Mar 5, 2026
traded Mar 3, 2026
+2dSEC FORM 4

Evidence

Lang Matthew
COO & GC · Apr 23, 2026
  • ← Insider ofevidence
    Coll Crespo BlasCHIEF MEDICAL OFFICER · Mar 5, 2026
  • ← Insider ofevidence
    Lin XichenCHIEF SCIENTIFIC OFFICER · Mar 5, 2026
  • ← Insider ofevidence
    Ma YingliCHIEF TECHNOLOGY OFFICER · Mar 5, 2026
  • ← Insider ofevidence
    Yoon JunCHIEF FINANCIAL OFFICER · Mar 5, 2026

    • Planned sales and 5% stakes

    Form 144, 13D and 13G
    • FMFMR LLCPassive holder · crossed on Sep 30, 2026 · 32.09M shares15% of class13G amendment · filed Nov 5, 2026